Literature DB >> 18500743

Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003.

Amy Downing1, Xue Qin Yu, Julia Newton-Bishop, David Forman.   

Abstract

The aim of this study was to compare trends in prognostic factors and survival from cutaneous melanoma between 1993 and 2003 in 2 populations with dramatically different underlying incidence rates [Yorkshire, UK, and New South Wales (NSW), Australia] and to look at whether the greater investment in melanoma prevention and early detection in Australia has resulted in any relative differences in survival. Patients diagnosed with invasive melanoma between 1993 and 2003 in Yorkshire (n = 4,170) and NSW (n = 30,520) were identified from cancer registry databases and prognostic information (age, sex, socioeconomic background, tumour site and Breslow thickness) was extracted. Age-standardised incidence rates, 5-year relative survival and relative excess risk of death were calculated. Between 1993-1995 and 2001-2003, the incidence of melanoma increased in both areas. These increases were mainly seen in tumours with thickness <or=1 mm. Five-year relative survival was 86.9% (95% CI 85.2-88.5) in Yorkshire and 88.6% (95% CI 88.1-89.1) in NSW. Compared with that in NSW, survival in Yorkshire was lower for males and for those living in the most deprived areas. Despite the increase in good prognosis of thin tumours, there was no significant change in survival over the time period in either area. After adjustment for differences in prognostic factors, the relative excess risk of death in Yorkshire compared to that in NSW reduced from 1.36 (95% CI 1.20-1.53) to 1.11 (95% CI 0.99-1.23). Differences in tumour thickness appeared to be the most important factor. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18500743     DOI: 10.1002/ijc.23495

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

3.  Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate.

Authors:  Julia A Newton-Bishop; Yu-Mei Chang; Faye Elliott; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Elaine Fitzgibbon; Kairen Kukalizch; Juliette Randerson-Moor; David E Elder; D Timothy Bishop; Jennifer H Barrett
Journal:  Eur J Cancer       Date:  2011-03       Impact factor: 9.162

4.  Development of a practical guide for the early recognition for malignant melanoma of the foot and nail unit.

Authors:  Ivan R Bristow; David Ar de Berker
Journal:  J Foot Ankle Res       Date:  2010-09-28       Impact factor: 2.303

Review 5.  Melanoma and vitamin D.

Authors:  Sinead Field; Julia A Newton-Bishop
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

6.  The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate.

Authors:  John R Davies; Yu-Mei Chang; Helen Snowden; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Kairen Kukalizch; Juliette Randerson-Moor; Faye Elliott; Julian Barth; Peter A Kanetsky; Mark Harland; D Timothy Bishop; Jennifer H Barrett; Julia A Newton-Bishop
Journal:  Cancer Causes Control       Date:  2011-08-19       Impact factor: 2.506

7.  Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.

Authors:  Cecilia Herraiz; Fernando Calvo; Pahini Pandya; Gaia Cantelli; Irene Rodriguez-Hernandez; Jose L Orgaz; NaRa Kang; Tinghine Chu; Erik Sahai; Victoria Sanz-Moreno
Journal:  J Natl Cancer Inst       Date:  2015-10-13       Impact factor: 13.506

8.  Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.

Authors:  Olaf Schoffer; Stefanie Schülein; Gerlinde Arand; Hans Arnholdt; Dieter Baaske; Ralf C Bargou; Nikolaus Becker; Matthias W Beckmann; Yves Bodack; Beatrix Böhme; Tayfun Bozkurt; Regine Breitsprecher; Andre Buchali; Elke Burger; Ulrike Burger; Klaus Dommisch; Gudrun Elsner; Karin Fernschild; Ulrike Flintzer; Uwe Funke; Michael Gerken; Hubert Göbel; Norbert Grobe; Vera Gumpp; Lucie Heinzerling; Lana Raffaela Kempfer; Alexander Kiani; Monika Klinkhammer-Schalke; Sabine Klöcking; Ute Kreibich; Katrin Knabner; Peter Kuhn; Stine Lutze; Uwe Mäder; Tanja Maisel; Jan Maschke; Martin Middeke; Andreas Neubauer; Antje Niedostatek; Anabelle Opazo-Saez; Christoph Peters; Beatrice Schell; Gerhard Schenkirsch; Harald Schmalenberg; Peter Schmidt; Constanze Schneider; Birgit Schubotz; Anika Seide; Paul Strecker; Sabine Taubenheim; Matthias Wackes; Steffen Weiß; Claudia Welke; Carmen Werner; Christian Wittekind; Jörg Wulff; Heike Zettl; Stefanie J Klug
Journal:  BMC Cancer       Date:  2016-12-05       Impact factor: 4.430

9.  Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).

Authors:  Veronica Di Carlo; Charles A Stiller; Nora Eisemann; Andrea Bordoni; Melissa Matz; Maria P Curado; Laetitia Daubisse-Marliac; Mikhail Valkov; Jean-Luc Bulliard; David Morrison; Chris Johnson; Fabio Girardi; Rafael Marcos-Gragera; Mario Šekerija; Siri Larønningen; Eunice Sirri; Michel P Coleman; Claudia Allemani
Journal:  Br J Dermatol       Date:  2022-07-28       Impact factor: 11.113

10.  Cancer survival in New South Wales, Australia: socioeconomic disparities remain despite overall improvements.

Authors:  Julia F Stanbury; Peter D Baade; Yan Yu; Xue Qin Yu
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.